Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

NLM Logo

Crizotinib MeSH Descriptor Data 2025


MeSH Heading
Crizotinib
Tree Number(s)
D03.383.621.154
D03.383.725.050.263
Unique ID
D000077547
RDF Unique Identifier
http://id.nlm.nih.gov/mesh/D000077547
Scope Note
A piperidine and aminopyridine derivative that acts as an inhibitor of RECEPTOR PROTEIN-TYROSINE KINASES, including ANAPLASTIC LYMPHOMA KINASE (ALK) and HEPATOCYTE GROWTH FACTOR RECEPTOR (HGFR; c-Met). It is used in the treatment of NON-SMALL CELL LUNG CANCER.
Entry Term(s)
PF 02341066
PF-02341066
PF-2341066
PF02341066
Xalkori
Pharm Action
Antineoplastic Agents
Tyrosine Kinase Inhibitors
Registry Numbers
53AH36668S
0
CAS Type 1 Name
2-Pyridinamine, 3-((1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(4-piperidinyl)-1H-pyrazol-4-yl)-
Public MeSH Note
2010; CRIZOTINIB was indexed under PYRAZOLES and PYRIDINES 2010-2018
History Note
2019 (2010)
Date Established
2019/01/01
Date of Entry
2018/07/09
Revision Date
2023/08/04
Crizotinib Preferred
PF-02341066 Narrower
Xalkori Narrower
page delivered in 0.154s